
CDTX
Healthcare · Biotechnology · $6.96B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now · -5.6% over 90 days · 30-day revisions 3 up, 3 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2025 | Time not confirmed | -2.77 | -3.10 | -11.9% |
| Aug 7, 2025 | Time not confirmed | -3.04 | -1.65 | +45.7% |
| Apr 21, 2025 | After the close | -3.47 | -1.66 | +52.2% |
| Mar 7, 2025 | Time not confirmed | -3.67 | -5.38 | -46.5% |
| Oct 31, 2024 | Before the open | -4.25 | -2.45 | +42.4% |
| Aug 13, 2024 | After the close | -3.22 | -19.99 | -520.8% |
| May 15, 2024 | After the close | -0.20 | -2.28 | -1040.0% |
| Mar 27, 2024 | Before the open | -0.10 | -0.04 | +60.0% |
| Nov 2, 2023 | After the close | -0.16 | -0.09 | +43.8% |
| Aug 3, 2023 | After the close | -0.13 | -0.14 | -7.7% |
| May 11, 2023 | After the close | -0.04 | 0.03 | +175.0% |
| Mar 23, 2023 | Before the open | -0.17 | -0.19 | -11.8% |
| Nov 3, 2022 | After the close | 0.18 |
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections…
| 0.17 |
| -5.6% |
| Aug 9, 2022 | After the close | -0.28 | -0.19 | +32.1% |
| May 11, 2022 | After the close | -0.29 | -0.27 | +6.9% |
| Mar 7, 2022 | After the close | -0.34 | -0.26 | +23.5% |
| Nov 10, 2021 | After the close | -0.36 | -0.37 | -2.8% |
| Aug 12, 2021 | After the close | -0.08 | 0.18 | +325.0% |
| May 13, 2021 | After the close | -0.26 | -0.39 | -50.0% |
| Feb 25, 2021 | After the close | -0.24 | -0.49 | -104.2% |
| Nov 5, 2020 | After the close | -0.38 | -0.41 | -7.9% |
| Aug 13, 2020 | After the close | -0.28 | -0.45 | -60.7% |
| May 13, 2020 | After the close | -0.34 | -0.46 | -35.3% |
| Mar 4, 2020 | Before the open | -0.43 | -0.42 | +2.3% |
| Nov 7, 2019 | After the close | -0.26 | 0.08 | +130.8% |
| Aug 8, 2019 | After the close | -0.57 | -0.49 | +14.0% |
| May 9, 2019 | After the close | -0.60 | -0.60 | 0.0% |
| Feb 28, 2019 | After the close | -0.59 | -0.44 | +25.4% |
| Nov 8, 2018 | After the close | -0.60 | -0.49 | +18.3% |
| Aug 8, 2018 | After the close | -0.66 | -1.13 | -71.2% |
| May 10, 2018 | After the close | -0.64 | -0.80 | -25.0% |
| Feb 27, 2018 | After the close | -0.76 | -0.69 | +9.2% |